两种药物联合治疗支气管哮喘慢性持续期的临床分析

Clinical Analysis of Two Drugs in the Treatment of Chronic Persistent Asthma

目的探究孟鲁司特钠联合布地奈德福莫特罗治疗支气管哮喘慢性持续期的临床效果。方法选取2018年1月—2019年1月本院门诊长期随诊的支气管哮喘慢性持续期患者80例,随机分为两组,对照组单独接受布地奈德福莫特罗治疗,观察组采用布地奈德福莫特罗联合孟鲁司特治疗,比较两组临床治疗效果。结果观察者哮喘控制有效率90.0%,高于对照组的70.0%,差异有统计学意义(P<0.05);治疗前两组患者肺功能指标比较差异均无统计学意义(P> 0.05),治疗后,观察组第1秒用力呼气容积为(2.7±0.7)L,用力肺活量为(3.2±0.6)L,呼气峰流速为(4.7±1.3)L/min,均显著优于对照组,组间比较差异均有统计学意义(P <0.05)。结论孟鲁司特钠联合布地奈德福莫特罗治疗支气管哮喘慢性持续期的临床效果显著。

Objective To explore the clinical effect of montelukast sodium combined with budesonide and formoterol in the treatment of chronic persistent bronchial asthma.Methods From January 2018 to January 2019,80 patients with chronic duration of bronchial asthma were randomly divided into two groups.The control group was treated with budesonide alone and the observation group was treated with budesonide combined with montelukast.The clinical effects of the two groups were compared.Results The effective rate of asthma control was 90.0%in the observation group,which was higher than 70.0%in the control group,the difference was statistically significant(P<0.05).There was no significant difference in lung function between the two groups before treatment(P>0.05).After treatment,the forced expiratory volume,forced vital capacity and peak expiratory flow rate of the observation group in the first second were(2.7±0.7)L,(3.2±0.6)L and(4.7±1.3)L/min in the observation group,which were better than those in the control group,the differences were statistically significant(P<0.05).Conclusion The clinical effect of montelukast sodium combined with budesonide in the treatment of chronic persistent stage of bronchial asthma is significant.